Method for producing human recombinant plasminogen activator protein with transgenic sheep in large scale

Abstract

The invention belongs to the field of bioengineering, and provides a new sequence of a human recombinant plasminogen activator, shown as SEQ ID No. (Sequence Identification Number) 1. The sequence can be used for preparing a mammary gland specificity expression human recombinant fibrinogen activator. The fact that an animal expression recombinant product in the DNA (Deoxyribonucleic Acid) sequence can facilitate fibrinolysis is tested and verified. The invention further discloses a structure of a mammary gland expression vector for preparing hrPA (human recombinant Plasminogen Activator) transgenic sheep. A method comprises the steps that cells are subjected to foreign gene transfection; the cells transfected with foreign genes are screened; transgenic nuclear transplantation is performed; and transgenic clone sheep is obtained. The technology can be used for preparing thrombolytic medicines for treating human cardiovascular diseases in a large scale, and is low in production cost and high in safety, and the product activity is high. The method has a completely proprietary intellectual property right; a subsequent development product is an independent product; and the method has a wide industrial prospect and a great economic benefit.

Description

technical field [0001] This technology combines genetic engineering and cell engineering technology, and belongs to the technical invention patent in the field of bioengineering. This technology is applied to large-scale production of human recombinant plasminogen activator (hrPA), and its production cost is significantly lower than that of cell culture or industrial fermentation. The production process is simple, no expensive instruments and equipment are required, and the biopharmaceutical materials obtained have higher activity than those prepared by other methods, and have good compatibility with the human body. Background technique [0002] Animal mammary gland bioreactor technology refers to the use of mammalian mammary gland-specific promoter elements to construct expression vectors and prepare transgenic animals, so that foreign genes can be expressed in the mammary glands of transgenic animals, and recombinant proteins can be obtained from animal milk. High commerci...

AI Technical Summary

Problems solved by technology

[0007] The third-generation thrombolytic drugs are clinically competitive because of their long half-life and few side effects, but they are relatively expensive.

[0009] To sum up, at present, t-PA is the representative of thrombolytic drugs clinically used in the treatment of thrombosis, which is mainly produced by prokaryotes and mammalian cells. and other defects, resulting in high price and high clinical treatment cost

In addition, the half-life of rPA in the blood is very short (3-5 minutes), making it necessary to maintain its effective concentration in clinical treatment by intravenous infusion of large doses, thus increasing the risk of systemic bleeding

In addition, biopharmaceuticals produced by prokaryotes are less compatible with the human body than biopharmaceuticals produced by mammals, have higher immunogenicity, and are prone to allergies

Images